# The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

> **NCT05438875** · PHASE3 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 96 (actual)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** all-trans retinoic acid
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT05438875
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438875, "The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05438875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*